Hologic, Inc.(HOLX) Stock Research - Grey Stern Research
Loading...

Hologic, Inc. (HOLX) Stock Analysis

$68.75 (-2.07%)

HOLX Financial Performance


Use the table below to view Hologic, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $68.75 -
52 Week Low $68.61 -
52 Week High $84.67 -
Market Cap $15.6 Billion 5/12
Gross Margin 56% 4/12
Profit Margin 18% 2/12
EBITDA margin 23% 3/12
Q3 - 2024 Revenue $987.9 Million 4/12
Q3 - 2024 Earnings $178.6 Million 3/12
Q3 - 2024 Free Cash Flow $0 Million 10/12
Trailing 4 Quarters Revenue $3.3 Billion 4/12
Trailing 4 Quarters Earnings $789.5 Million 3/12
Quarterly Earnings Growth 97% 2/12
Annual Earnings Growth 2655% 1/12
Quarterly Revenue Growth 5% 7/12
Annual Revenue Growth -15% 11/12
Cash On Hand $2.2 Billion 1/12
Short Term Debt $37.5 Million 5/12
Long Term Debt $2.5 Billion 3/12

Hologic, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Hologic, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 19.76 9/12
PS 4.74 4/12
PB 3.04 6/12
PC 7.22 11/12
Liabilities to Equity 0.78 6/12
ROA 0.09 3/12
ROE 0.15 3/12
Current Ratio 2.27 7/12
Quick Ratio 0.58 1/12
Long Term Debt to Equity 0.49 4/12
Debt to Equity 0.49 4/12
Burn Rate -31.15 12/12
Cash to Cap 0.14 2/12
CCR 10/12
EV to EBITDA 69.43 9/12
EV to Revenue 4.85 4/12

Company Details

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

CEO: Mr. Stephen MacMillan

Website: https://www.hologic.com

Address: 250 Campus Dr Marlborough, MASSACHUSETTS

Exchange: NASDAQ Global Select

Industry: Medical Instruments & Supplies

Hologic, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Hologic, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Becton, Dickinson and Company BDX $67.5 Billion
ResMed Inc. RMD $34.3 Billion
The Cooper Companies, Inc. COO $18.1 Billion
Haemonetics Corporation HAE $3.8 Billion
Teleflex Incorporated TFX $8.2 Billion
West Pharmaceutical Services, Inc. WST $23.8 Billion
Merit Medical Systems, Inc. MMSI $5.9 Billion
AngioDynamics, Inc. ANGO $492.5 Million
ICU Medical, Inc. ICUI $4.1 Billion
AptarGroup, Inc. ATR $10.4 Billion
Envista Holdings Corporation NVST $3.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
HOLX Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 987.9 Million $178.6 Million
Q3 2024 $ 1.0 Billion $194.5 Million
Q2 2024 $ 1.0 Billion $169.9 Million
Q1 2024 $ 277.9 Million $246.5 Million
Q4 2023 $ 945.3 Million $90.6 Million
Q3 2023 $ 984.4 Million -$40.5 Million
Q2 2023 $ 1.0 Billion $218.5 Million
Q1 2023 $ 1.1 Billion $187.4 Million

View All

HOLX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $2.2 Billion $9.2 Billion $2.5 Billion $5.1 Billion
Q3 2024 $2.4 Billion $8.9 Billion $2.6 Billion $5.0 Billion
Q2 2024 $2.2 Billion $8.7 Billion $2.6 Billion $4.8 Billion
Q1 2024 $1.9 Billion $8.5 Billion $2.6 Billion $4.7 Billion
Q4 2023 $2.7 Billion $9.1 Billion $2.8 Billion $5.0 Billion
Q3 2023 $2.8 Billion $9.3 Billion $2.8 Billion $5.2 Billion
Q2 2023 $2.6 Billion $9.4 Billion $2.8 Billion $5.3 Billion
Q1 2023 $2.4 Billion $9.3 Billion $2.8 Billion $5.1 Billion

View All

HOLX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $361.9 Million -$43.9 Million $259.1 Million
Q2 2024 $264.4 Million -$28.0 Million $247.9 Million
Q1 2024 $197.3 Million -$22.7 Million -$823.6 Million
Q4 2023 $206.2 Million -$52.5 Million -$9.3 Million
Q3 2023 $296.3 Million -$36.5 Million $182.8 Million
Q2 2023 $174.2 Million -$32.1 Million $140.9 Million
Q1 2023 $224.3 Million -$29.1 Million $101.8 Million
Q4 2022 $137.0 Million -$31.6 Million -$35.8 Million

View All